These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34187265)

  • 1. OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation.
    Cheng F; Ahmed F
    Expert Opin Drug Saf; 2021 Nov; 20(11):1275-1289. PubMed ID: 34187265
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I; Martínez-Velasco E; Rojo A; Hernando A; Ruiz M; Carreres A; Porqueres E; Herrero S; Iglesias F; Guerrero AL
    J Headache Pain; 2016 Dec; 17(1):112. PubMed ID: 27957623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Winner PK; Kabbouche M; Yonker M; Wangsadipura V; Lum A; Brin MF
    Headache; 2020 Mar; 60(3):564-575. PubMed ID: 32037549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine.
    Gonzalez-Martinez A; Rodríguez Vázquez E; de la Red Gallego H; García-Azorín D; Gallego de La Sacristana M; Guerrero Peral ÁL; Gago-Veiga AB
    Headache; 2020 Jan; 60(1):153-161. PubMed ID: 31691958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R; Athwal B; Gryglas-Dworak A; Frattale I; Latysheva N; Ornello R; Pozo-Rosich P; Sacco S; Torres Ferrus M; Stark CD
    Headache; 2020 Sep; 60(8):1673-1682. PubMed ID: 32797631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What is the optimal dose for the prophylactic treatment of chronic migraine patients?].
    Irimia P; Esteve-Belloch P; Murie-Fernandez M; Martinez-Vila E
    Rev Neurol; 2014 Mar; 58 Suppl 2():S13-9. PubMed ID: 24687880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
    Frampton JE; Silberstein S
    Drugs; 2018 Apr; 78(5):589-600. PubMed ID: 29532439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use.
    Frampton JE
    CNS Drugs; 2020 Dec; 34(12):1287-1298. PubMed ID: 33314008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
    Winner PK; Blumenfeld AM; Eross EJ; Orejudos AC; Mirjah DL; Adams AM; Brin MF
    Drug Saf; 2019 Aug; 42(8):1013-1024. PubMed ID: 31102144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
    J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE
    Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Onabotulinumtoxin A in the treatment of chronic migraine].
    Láinez-Andrés JM
    Rev Neurol; 2012 Apr; 54 Suppl 2():S39-50. PubMed ID: 22532242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine.
    Diener HC; Dodick DW; Turkel CC; Demos G; Degryse RE; Earl NL; Brin MF
    Eur J Neurol; 2014 Jun; 21(6):851-9. PubMed ID: 24628923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
    Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine.
    Santos-Lasaosa S; Cuadrado ML; Gago-Veiga AB; Guerrero-Peral AL; Irimia P; Láinez JM; Leira R; Pascual J; Porta-Etessam J; Sánchez Del Río M; Viguera Romero J; Pozo-Rosich P
    Neurologia (Engl Ed); 2020 Oct; 35(8):568-578. PubMed ID: 29169811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study.
    García-Azorín D; Martínez B; Gutiérrez M; Ruiz-Piñero M; Echavarría A; Sierra Á; Guerrero ÁL
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
    Lyseng-Williamson KA; Frampton JE
    CNS Drugs; 2012 Aug; 26(8):717-23. PubMed ID: 22784019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.